Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Surveillance Outcome Program (AESOP) Bloodstream Infection Annual Report 2023

Authors

  • Geoffrey Coombs School of Medical, Molecular and Forensic Sciences, Murdoch University, Murdoch, Western Australia, Australia
  • Denise A Daley Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia; Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
  • Princey Shoby School of Medical, Molecular and Forensic Sciences, Murdoch University, Murdoch, Western Australia, Australia
  • Auriane Form School of Medical, Molecular and Forensic Sciences, Murdoch University, Murdoch, Western Australia, Australia
  • Shakeel Mowlaboccus School of Medical, Molecular and Forensic Sciences, Murdoch University, Murdoch, Western Australia, Australia; Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

DOI:

https://doi.org/10.33321/cdi.2024.48.56

Keywords:

Australian Group on Antimicrobial Resistance (AGAR), antimicrobial resistance surveillance, Enterococcus faecium, Enterococcus faecalis, vancomycin resistant enterococci (VRE), bacteraemia

Abstract

From 1 January to 31 December 2023, fifty-six institutions across Australia participated in the Australian Enterococcal Surveillance Outcome Program (AESOP). The aim of AESOP 2023 was to determine the proportion of enterococcal bacteraemia isolates in Australia that were antimicrobial resistant, and to determine the Enterococcus faecium molecular epidemiology. Of the 1,599 unique episodes of enterococcal bacteraemia investigated, 92.9% were caused by either E. faecalis (51.8%) or E. faecium (41.1%). Ampicillin and vancomycin resistance were not detected in E. faecalis but were detected in 94.2% and 50.8% of E. faecium respectively. Two linezolid-resistant E. faecalis were identified in 2023. Both isolates had linezolid minimum inhibitory concentrations (MICs) of 6.0 mg/L, were vancomycin susceptible, and harboured the optrA gene.
Overall, 53.2% of E. faecium harboured either the vanA or the vanB gene; of these, 27.3% harboured vanA, 72.1% harboured vanB, and 0.6% harboured vanA and vanB. The percentage of vancomycin-resistant E. faecium bacteraemia isolates in Australia remains substantially higher than that recorded in most European countries. The E. faecium isolates consisted of 58 multi-locus sequence types (STs); 85.7% of isolates were classified into seven major STs, each containing ten or more isolates. All major STs belonged to clonal complex (CC) 17, a global hospital-adapted polyclonal E. faecium CC. The major STs (ST78, ST1424, ST17, ST80, ST796, ST1421 and ST555) were found across most regions of Australia, with ST78 identified in all regions. Overall, 58.3% of isolates belonging to the seven major STs harboured the vanA or vanB gene. AESOP 2023 has shown that enterococcal bacteraemia episodes in Australia continues to be frequently caused by polyclonal ampicillin-resistant high-level gentamicin-resistant vanA- or vanB-positive E. faecium which have limited treatment options.

Downloads

Download data is not yet available.

References

Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007;58(2):163–70. doi: https://doi.org/10.1016/j.diagmicrobio.2006.12.022.

Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev. 1990;3(1):46–65. doi: https://doi.org/10.1128/CMR.3.1.46.

Pinholt M, Ostergaard C, Arpi M, Bruun NE, Schønheyder HC, Gradel KO et al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006–2009: a population-based cohort study. Clin Microbiol Infect. 2014;20(2):145–51. doi: https://doi.org/ 10.1111/1469-0691.12236.

Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12. doi: https://doi.org/10.1086/595011.

World Health Organization (WHO). WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: WHO; 17 May 2024. Available from: https://www.who.int/publications/i/item/9789240093461.

Christiansen KJ, Turnidge JD, Bell JM, George NM, Pearson JC, Australian Group on Antimicrobian Resistance. Prevalence of antimicrobial resistance in Enterococcus isolates in Australia, 2005: report from the Australian Group on Antimicrobial Resistance. Commun Dis Intell Q Rep. 2007;31(4):392–7.

Coombs GW, Daley D, Pearson JC, Ingram PR. A change in the molecular epidemiology of vancomycin resistant enterococci in Western Australia. Pathology. 2014;46(1):73–5. doi: https://doi.org/10.1097/PAT.0000000000000038.

Coombs GW, Pearson JC, Daley DA, Le T, Robinson OJ, Gottlieb T et al. Molecular epidemiology of enterococcal bacteremia in Australia. J Clin Microbiol. 2014;52(3):897–905. doi: https://doi.org/10.1128/JCM.03286-13.

The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0. Basel: EUCAST; 1 January 2024. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_14.0_Breakpoint_Tables.pdf.

Coombs GW, Daley DA, Lee YT, Pang S. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2017. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.42.

Coombs GW, Daley DA, Mowlaboccus S, Lee YT, Pang S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2018. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.19.

Coombs GW, Daley DA, Mowlaboccus S, Pang S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2019. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.72.

Coombs GW, Daley DA, Yee NWT, Shoby P, Mowlaboccus S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2020. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/cdi.2022.46.17.

Coombs GW, Daley DA, Yee NWT, Shoby P, Mowlaboccus S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Surveillance Outcome Program (AESOP) – Bloodstream Infection Annual Report 2021. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/cdi.2022.46.77.

European Centre for Disease Prevention and Control (ECDC). European Antimicrobial Resistance Surveillance Network (EARS-Net). [Webpage.] Solna: ECDC; 17 November 2023. [Accessed on 2 April 2024.] Available from: https://www.ecdc.europa.eu/en/about-us/networks/disease-networks-and-laboratory-networks/ears-net-data.

ECDC. Surveillance Atlas of Infectious Diseases. [Webpage.] Solna: ECDC; 28 April 2023. Available from: https://www.ecdc.europa.eu/en/surveillance-atlas-infectious-diseases.

Downloads

Published

18/12/24

How to Cite

Coombs, Geoffrey, Denise A Daley, Princey Shoby, Auriane Form, and Shakeel Mowlaboccus. 2024. “Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Surveillance Outcome Program (AESOP) Bloodstream Infection Annual Report 2023”. Communicable Diseases Intelligence 48 (December). https://doi.org/10.33321/cdi.2024.48.56.

Issue

Vol. 48 (2024)

Section

Annual report

Categories

License

Copyright (c) 2024 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 > >>